to support optimizing pseudovirus platforms for COVID-19 product innovation | Pandemic PACT Tracker

Key facts

Disease
COVID-19
start year
2020
Known Financial Commitments (USD)
$208,575
Funder
Gates Foundation
Principal Investigator
N/A
Research Location
China
Lead Research Institution
National Institutes for Food and Drug Control
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
Innovation
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:42 minutes ago

View all publications at Europe PMC

Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.

The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.

Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.

Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants.

Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants.

Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses.

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay.